Table S1. PubMed search strategy for North Carolina SARS-CoV-2 seroprevalence estimates

1	(Serology[Mesh] OR "Serologic Tests"[Mesh] OR Immunoglobulins[Mesh] OR
	"Seroepidemiologic Studies"[Majr] OR sero*[tiab] OR antibody[tiab] OR "anti-body"[tiab]
	OR antibodies[tiab])
2	
	OR "covid 2019"[tiab] OR "SARS-CoV-2"[tiab] OR "severe acute respiratory syndrome
	coronavirus 2"[tiab])
3	"COVID-19 Serological Testing"[Mesh]
4	("North Carolina"[Mesh] OR "North Carolina"[tiab] OR "Charlotte"[tiab] OR "Raleigh"[tiab]
	OR "Greensboro"[tiab] OR "Durham"[tiab] OR "Winson-Salem"[tiab] OR "Fayetteville"[tiab]
	OR "Cary"[tiab] OR "Wilmington"[tiab])
5	(2019/12[Date - Publication]: 3000[Date - Publication])
6	((1 AND 2) OR 3) AND 4 AND 5

Note: 27 studies identified, none met all criteria or were not duplicates from SeroHub. Last date of search was October 16, 2023.

Table S2. SARS-CoV-2 infection-induced seroprevalence among the North Carolina general population by midpoint between collection start and end dates

Study	Population description	Assay	Collection dates (year- month-day)	Sampl e size	Infectio n- induced seropre valence, % (95% CI)
Barzin, 2020	Inpatients unrelated to COVID-19	Abbot Architect N	2020-03-03 to 2020-06-04	1449	0.7
Barzin, 2020	Asymptomatic people at NC outpatient clinics	Abbot Architect N	2020-04-28 to 2020-06-19	2973	0.8
COVID-19 Community Research Partnership Study Group, 2021	Wake Forest Baptist Health and Atrium Health systems, general pop	Syntron/Tianjin New Bay Bioresearch N lateral flow assay (LFA)	2020-04-16 to 2021-01-04	11468	10.2
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-02-08 to 2021-02-18	1309	20.6 (18.3,23)
CDC blood donor surveillance	Central and Western NC region blood donors	Roche Elecsys N	2021-02-01 to 2021-02-28	4208	16.4 (14.6,18. 5)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-02-22 to 2021-03-01	1172	22.5 (19.8,25)

CDC commercial lab	NC commercial lab	Roche Elecsys	2021-03-09 to	1140	23.8
surveillance	remnant specimens	N	2021-03-03 to	1140	(21.1,26.
our voillarioo	Tommani opecimene		2021 00 10		6)
CDC blood donor	Central and Western	Roche Elecsys	2021-03-01 to	4072	18
surveillance	NC region blood	N	2021-03-31		(16.2,19.
	donors				8)
CDC commercial lab	NC commercial lab	Roche Elecsys	2021-03-24 to	1362	22.9
surveillance	remnant specimens	N	2021-03-31		(20.5,25.
	·				6)
CDC commercial lab	NC commercial lab	Roche Elecsys	2021-04-05 to	1304	23
surveillance	remnant specimens	N	2021-04-14		(20.2,25.
					6)
CDC blood donor	Central and Western	Roche Elecsys	2021-04-01 to	4195	20
surveillance	NC region blood	N	2021-04-30		(17.9,22.
	donors				3)
CDC commercial lab	NC commercial lab	Roche Elecsys	2021-04-19 to	1303	21.9
surveillance	remnant specimens	N	2021-04-28		(19.2,24.
					6)
CDC commercial lab	NC commercial lab	Roche Elecsys	2021-05-03 to	1307	24.4
surveillance	remnant specimens	N	2021-05-12		(22.1,27)
CDC blood donor	Central and Western	Roche Elecsys	2021-05-01 to	4159	19.5
surveillance	NC region blood	N	2021-05-31		(17.8,21.
000	donors	D . E.	0004.05.47.1	1070	2)
CDC commercial lab	NC commercial lab	Roche Elecsys	2021-05-17 to	1272	22.7
surveillance	remnant specimens	N	2021-05-29		(20.1,25.
CDC commercial lab	NC commercial lab	Doobo Florova	2024 05 24 to	1268	6) 23.8
CDC commercial lab surveillance		Roche Elecsys	2021-05-31 to 2021-06-09	1200	
Surveillarice	remnant specimens	IN	2021-00-09		(21.1,26. 4)
CDC blood donor	Central and Western	Roche Elecsys	2021-06-01 to	4157	18
surveillance	NC region blood	N	2021-06-30	4137	(16,20.1)
our veillarioe	donors		2021 00 00		(10,20.1)
CDC commercial lab	NC commercial lab	Roche Elecsys	2021-06-14 to	1315	22.8
surveillance	remnant specimens	N	2021-06-25	1010	(20.2,25.
our volliur 100	Tommanic opcomionic		2021 00 20		3)
CDC commercial lab	NC commercial lab	Roche Elecsys	2021-06-28 to	1302	22.6
surveillance	remnant specimens	N	2021-07-09		(20,25.2)
CDC blood donor	Central and Western	Roche Elecsys	2021-07-01 to	4168	18.7
surveillance	NC region blood	N	2021-07-31		(16.6,21.
	donors				1)
CDC blood donor	Central and Western	Roche Elecsys	2021-08-01 to	4226	20.7
surveillance	NC region blood	N	2021-08-31		(18.6,22.
	donors				9)
CDC blood donor	Central and Western	VITROS	2021-09-01 to	4312	23.6
surveillance	NC region blood	chemiluminesc	2021-09-30		(22,25.3)
	donors	ent totat Ig N,			
		Ortho Clinical			
		Diagnostics			
CDC commercial lab	NC commercial lab	Roche Elecsys	2021-09-06 to	1767	26.6
surveillance	remnant specimens	N	2021-10-02		(24.2,29.
					1)

CDC blood donor surveillance	Central and Western NC region blood donors	VITROS chemiluminesc ent totat Ig N, Ortho Clinical Diagnostics	2021-10-01 to 2021-10-31	4330	25 (22.9,27. 1)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-10-04 to 2021-10-30	1775	33.6 (30.7,36. 5)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-11-01 to 2021-11-24	1846	30.3 (27.7,33)
CDC blood donor surveillance	Central and Western NC region blood donors	VITROS chemiluminesc ent totat Ig N, Ortho Clinical Diagnostics	2021-11-01 to 2021-11-30	4311	27.7 (25.7,29. 6)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-11-29 to 2021-12-22	1833	34.5 (32.1,37. 2)
CDC blood donor surveillance	Central and Western NC region blood donors	VITROS chemiluminesc ent totat Ig N, Ortho Clinical Diagnostics	2021-12-01 to 2021-12-31	4071	28.1 (26.1,30)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2022-01-03 to 2022-01-20	1329	40 (36.7,43. 4)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2022-02-01 to 2022-02-18	1317	52 (48.9,55. 2)

Note: estimates overlapping with Animal Slaughtering and Processing industry enrollment (April 2, 2021 to July 28, 2022) are highlighted in grey. The minimum prevalence estimate overlapping with Animal Slaughtering and Processing industry enrollment (April 2, 2021 to July 28, 2022) was 18% and maximum 52%.

Table S3. Source of information (multiplex antibody and questionnaire data) for determining evidence of prior SARS-CoV-2 infection among adult (≥18) participants (N=236), concordant multiplex N/S and synthesis results highlighted green (n=220)

Questionnaire responses	Multiplex	Synthesis of antibody	n	l
	salivary	assay results and		l
	SARS-CoV-2	reported viral test and		l
	IgG antibody	vaccination history		l
	assay results	_		

Ever positive viral SARS-CoV-2 test	≥1 vaccine dose	N/S	Evidence of prior infection	26
Ever positive viral SARS-CoV-2 test	≥1 vaccine dose	S	Evidence of prior infection	2
Ever positive viral SARS-CoV-2 test	≥1 vaccine dose	Unknown	Evidence of prior infection	2
Ever positive viral SARS-CoV-2 test	No vaccine	N/S	Evidence of prior infection	9
Ever positive viral SARS-CoV-2 test	No vaccine	none	Evidence of prior infection	2
Ever positive viral SARS-CoV-2 test	No vaccine	Unknown	Evidence of prior infection	3
Ever positive viral SARS-CoV-2 test	Unknown	N/S	Evidence of prior infection	1
No positive viral SARS-CoV-2 test	≥1 vaccine dose	N/S	Evidence of prior infection	26
No positive viral SARS-CoV-2 test	No vaccine	N/S	Evidence of prior infection	16
No positive viral SARS-CoV-2 test	No vaccine	S	Evidence of prior infection	1
Unknown	≥1 vaccine dose	N/S	Evidence of prior infection	20
Unknown	No vaccine	N/S	Evidence of prior infection	29
Unknown	No vaccine	S	Evidence of prior infection	6
Unknown	Unknown	N/S	Evidence of prior infection	1
No positive viral SARS-CoV-2 test	≥1 vaccine dose	S	No evidence of prior infection	27
No positive viral SARS-CoV-2 test	≥1 vaccine dose	none	No evidence of prior infection	6
No positive viral SARS-CoV-2 test	No vaccine	none	No evidence of prior infection	16
No positive viral SARS-CoV-2 test	Unknown	S	No evidence of prior infection	1
No positive viral SARS-CoV-2 test	Unknown	none	No evidence of prior infection	2
Unknown	≥1 vaccine dose	S	No evidence of prior infection	13
Unknown	≥1 vaccine dose	none	No evidence of prior infection	1
Unknown	No vaccine	none	No evidence of prior infection	26

Note: of 236 adult participants, 128 were positive for any evidence of prior SARS-CoV-2 infection and N/S IgG; 92 were negative for any evidence of infection and N/S IgG; 11 were positive for evidence of infection and negative for N/S IgG; and 5 were positive for any evidence of infection and invalid for N/S IgG. Of 167 employed adult participants, 93 were positive for any

evidence of prior SARS-CoV-2 infection and N/S IgG; 65 were negative for any evidence of infection and N/S IgG; 5 were positive for evidence of infection and negative for N/S IgG; and 4 were positive for any evidence of infection and invalid for N/S IgG.

Table S4. PubMed search strategy for US animal slaughtering and processing worker SARS-CoV-2 seroprevalence estimates

1	(Serology[Mesh] OR "Serologic Tests"[Mesh] OR Immunoglobulins[Mesh] OR
	"Seroepidemiologic Studies"[Majr] OR sero*[tiab] OR antibody[tiab] OR "anti-body"[tiab]
	OR antibodies[tiab])
2	("COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh] OR "COVID-19"[tiab] OR "covid 2019"[tiab]
	OR "SARS-CoV-2"[tiab] OR "severe acute respiratory syndrome coronavirus 2"[tiab])
3	"COVID-19 Serological Testing"[Mesh]
4	("Meat-Packing Industry"[Mesh] OR "Poultry"[Mesh] OR "Cattle"[Mesh] OR "Swine"[Mesh]
	OR "meat pack*"[tiab] OR meatpack*[tiab] OR "meat process*"[tiab] OR slaughterer*[tiab]
	OR cutter*[tiab] OR meat[tiab] OR poultry[tiab] OR cattle[tiab] OR swine[tiab])
5	("Occupational Groups"[Mesh] OR "Work"[Mesh] OR "Workplace"[Mesh] OR work*[tiab]
	OR occupation*[tiab] OR industry*[tiab])
6	(2019/12[Date - Publication]: 3000[Date - Publication])
7	((1 AND 2) OR 3) AND 4 AND 5 AND 6

Note: 20 studies identified, only 1 relevant and carried out in the US. Last date of search was December 14, 2023.

Table S5. Workplace characteristics and infection prevention and control measures by industry among adult (≥18) employed participants (N=167), North Carolina, 2021-2022

Characteristic, n (%)	Animal slaughtering & processing, N = 57	Health care & social assistance, N = 20	Animal production & aquaculture, N = 13	Other, N = 77	p-value for any difference
Essential worker	56 (98%)	16 (80%)	13 (100%)	39 (52%)	<0.001ª
Worked in person past 2 weeks (at all)	57 (100%)	20 (100%)	13 (100%)	62 (81%)	<0.001ª
Employees at worksite					
10 or fewer	5 (8.8%)	7 (39%)	9 (69%)	22 (31%)	

11-100	10 (18%)	8 (44%)	3 (23%)	(38%)	
101-1000	21 (37%)	1 (5.6%)	1 (7.7%)	20 (28%)	
>1000	21 (37%)	2 (11%)	0 (0%)	(2.8%)	
Hours worked per week				,	<0.001a
<40	1 (1.8%)	5 (25%)	3 (23%)	26 (34%)	
40	17 (30%)	12 (60%)	2 (15%)	21 (27%)	
>40	39 (68%)	3 (15%)	8 (62%)	30 (39%)	
Aware of COVID-19 cases at work past 2 weeks	49 (86%)	16 (80%)	10 (83%)	68 (88%)	0.7ª
Able to maintain 6+ feet of distance	42 (75%)	12 (60%)	12 (92%)	61 (79%)	0.2ª
Could isolate if COVID-19+	51 (96%)	20 (100%)	10 (77%)	70 (93%)	0.078ª
Could quarantine if COVID-19 exposed	49 (92%)	20 (100%)	11 (85%)	72 (96%)	0.2ª
Infection prevention and control measures					
Engineering controls					
Physical barriers between stations	18 (32%)	6 (30%)	2 (15%)	28 (36%)	0.5ª
Added hand washing stations	44 (77%)	14 (70%)	9 (69%)	47 (61%)	0.3ª
Administrative controls					
Change in workplace sick leave	12 (21%)	12 (60%)	1 (7.7%)	23 (30%)	0.004ª
COVID-19 testing at work	29 (51%)	11 (55%)	2 (15%)	16 (21%)	<0.001ª
Masks required	50 (88%)	18 (90%)	7 (54%)	55 (71%)	0.011ª
PPE					
Employer provides face masks (any type)	53 (93%)	18 (90%)	7 (54%)	63 (82%)	0.007 ^a
Employer provides N95/KN96/respirators	9 (16%)	7 (35%)	4 (31%)	13 (17%)	0.2ª
Employer provides surgical masks	36 (63%)	16 (80%)	4 (31%)	42 (55%)	0.030 ^b
Employer provides cloth masks	28 (49%)	4 (20%)	0 (0%)	33 (43%)	0.003 ^b
Employer provides face shields	28 (49%)	7 (35%)	3 (23%)	14 (18%)	0.001a
Employer provides hand protection	44 (77%)	12 (60%)	7 (54%)	(30%)	<0.001 ^b

^a Fisher's exact test for any difference in characteristic among industry categories

^b Pearson's Chi-squared test for any difference in characteristic among industry categories